CMV

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

Oligonucleotides Global Markets Report 2024: Historical Market Revenue Data from 2020 to 2022, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Diagnosis, Cytomegalovirus retinitis, PCR, Eurofins Scientific, Thermo Fisher Scientific, Disease, Oligonucleotide, CMV, ESG, Integration, Estimation, Research, RNA, DNA, Cancer, Competition, Infection, Agilent Technologies, Hepatitis, Spinal cord, In situ hybridization, Therapy, USD, FDA, Liver, Polymerase chain reaction, Fine chemical

The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.

Key Points: 
  • The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.
  • This report covers the worldwide market for oligonucleotide synthesis, which consists of four main product types: oligonucleotide drugs, synthesized oligos, equipment and reagents, and services.
  • Based on application, the market for oligonucleotide synthesis is divided into research diagnostics and therapeutics.
  • The report also covers approved drugs, the oligonucleotide synthesis process, innovative research, opportunities within the market and profiles of leading companies in the oligonucleotide synthesis industry.

Bull Attorneys® Announces Release of Truck Accident Lawyers Group Advertising Platform for Commercial Motor Vehicle Accident Litigation Practice

Retrieved on: 
Tuesday, March 26, 2024
CSA, Traffic, National highway, Federation, Transport, CMV, Death, FMCSA, Accident, Publication, Lawyer, National Safety Council, Book, Multimedia, NHTSA, NSC, Insurance

WICHITA, Kan., March 26, 2024 /PRNewswire/ -- Bull Attorneys® and Bradley A. Pistotnik are pleased to announce the release of an adjunct website related to their Commercial Motor Vehicle (CMV) litigation practice.

Key Points: 
  • WICHITA, Kan., March 26, 2024 /PRNewswire/ -- Bull Attorneys® and Bradley A. Pistotnik are pleased to announce the release of an adjunct website related to their Commercial Motor Vehicle (CMV) litigation practice.
  • Bradley A. Pistotnik, CEO of Bull Attorneys® created and authored the newly released site for Truck Accident Lawyers Group™ (TALG) which will be at Truckaccidentlawyersgroup.com .
  • It teaches the basic facts about the regulatory scheme of the federal government related to large truck crashes.
  • The lawyers from TALG have law licenses in different states, including Kansas, Nebraska, Oklahoma, Missouri, Colorado, Texas, Arkansas, Arizona, Illinois, Utah, and Florida.

Kamada Issues 2024 CEO Letter to Shareholders

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, KMDA, CMV, Hospital, Division, EMA, CSL Behring, Letter, Physician, Critical care, FDA, Technology transfer, Food, Growth, FEV1, AAT, Immunoglobulin G, Safety, University, European Medicines Agency, Food and Drug Administration, Pan American Health Organization, Patient, Plasma, Research, Partnership, Pharmaceutical industry

The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.

Key Points: 
  • The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.
  • Looking ahead, we expect the momentum from 2023 to extend throughout 2024, with profitability to be further increased as compared to last year.
  • These significant catalysts are propelling our continued annual double-digit profitable growth with substantial upside potential and limited downside risk.
  • On behalf of the entire Kamada team, we look forward to continuing to support patients and clinicians with the important lifesaving products that we develop, manufacture, and commercialize.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma

Retrieved on: 
Thursday, February 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Fast Track, CMV, BLA, Cell, Biologics license application, Cytomegalovirus, Interleukin, Safety, Therapy, Cytokine, Accelerated approval (FDA), Patient, NK, Clinical trial, Multiple myeloma, Rituximab, Lymphoma, Cancer, Priority review, Pharmaceutical industry

Companies granted Fast Track designation may be eligible for more frequent interactions with the FDA, Accelerated Approval and Priority Review, and Rolling Review of a Biologic License Application (BLA).

Key Points: 
  • Companies granted Fast Track designation may be eligible for more frequent interactions with the FDA, Accelerated Approval and Priority Review, and Rolling Review of a Biologic License Application (BLA).
  • “This designation highlights the promise of Indapta’s highly potent NK cell platform and will further accelerate clinical development of our lead drug candidate, IDP-023, for two of the largest unmet needs in B-cell driven blood cancers, non-Hodgkin’s lymphoma and multiple myeloma,” said Dr. Mark Frohlich, CEO of Indapta.
  • Patients being enrolled now in Indapta’s Phase 1 clinical trial are receiving up to three planned doses of IDP-023 with or without interleukin-2.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors with increased numbers of g-NK cells, with low donor-to-donor variability.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

EQS-News: AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS® for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

Retrieved on: 
Saturday, January 13, 2024
MSD, HSCT, Patient, Research, Kidney, Incidence, CMV, Merck & Co., Valganciclovir, EMA, Risk, Infection, Immunodeficiency, Food, Disease, EUR, FDA, Merck, MRK, Pharmaceutical industry

“Following the U.S. approval mid-2023, we are excited that our partner MSD now also received European approval for PREVYMIS® (letermovir) in its second indication, the prophylaxis of CMV infection in adult kidney transplanted patients at high risk.

Key Points: 
  • “Following the U.S. approval mid-2023, we are excited that our partner MSD now also received European approval for PREVYMIS® (letermovir) in its second indication, the prophylaxis of CMV infection in adult kidney transplanted patients at high risk.
  • In June 2023, the FDA and in December 2023 the EMA approved PREVYMIS® for prophylaxis of CMV disease in adult kidney transplant recipients at high risk.
  • Moreover, extended 200-day dosing for PREVYMIS® for CMV prophylaxis in adult HSCT recipients at risk for late CMV infection and disease was approved by the FDA in August 2023.
  • Approvals by national authorities was supported by a Phase 3, randomized, multicenter, double-blind, active comparator-controlled non-inferiority trial (P002, NCT03443869) in 589 adult kidney transplant recipients at high risk (CMV D+/R-).

Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer

Retrieved on: 
Thursday, January 11, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, NK, Patient, Therapy, CMV, Cytokine, University, Cancer, Interleukin, GMP, Lymphoma, Multiple myeloma, Safety, Cytomegalovirus, Daratumumab, MD Anderson Cancer Center, Cell, Vaccine

Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapy for the treatment of cancer, today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.

Key Points: 
  • Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapy for the treatment of cancer, today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.
  • The patients were treated at the University of Texas MD Anderson Cancer Center and NEXT Oncology, Virginia.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors with increased numbers of g-NK cells.
  • Indapta’s off-the-shelf g-NK cell therapy is further differentiated from other NK cell therapies in that it is a cryopreserved product with low variability.